Recent Updates
Recently added Catalysts
DTIL Positive Sentiment

Precision BioSciences to Participate in Upcoming November Investor Conferences

Friday, November 22, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Precision BioSciences, a clinical stage gene editing company, announced its participation in upcoming investor conferences in November 2024. The company is known for its proprietary ARCUS® platform, which focuses on developing in vivo gene editing therapies. This engagement reflects the company's commitment to transparency and investor relations.
Price reaction · baseline $6.5 (2024-11-21 close) · hit pre-market · clean, no other DTIL news in the window
day 0 close · peak
+11.7%
day 1
+11.4%
day 3
+9.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Precision BioSciences is actively engaging with investors.
  • Participation in conferences indicates confidence in their pipeline.
  • The company is utilizing innovative gene editing technology.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer

Full Press Release Details

DURHAM, N.C. –(BUSINESS WIRE)–Nov. 21, 2024– Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will participate in the

Frequently Asked Questions

What is Precision BioSciences known for?

Precision BioSciences is known for its proprietary ARCUS® platform for gene editing.

When will Precision BioSciences participate in investor conferences?

Precision BioSciences will participate in investor conferences in November 2024.

What type of therapies does Precision BioSciences develop?

The company develops in vivo gene editing therapies for sophisticated gene edits.

ShareAdd on Google
Tags: DTIL Viatris Investor Conferences Healthcare Precision BioSciences gene editing investor conferences ARCUS platform
Last updated: Nov 22, 2024

Biotech snapshot

Cash runway
$88M liquidity · $4M/mo burn
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-TPhase 1
Advanced Lung Cancer →

Catalyst track record

+24%
best trade around DTIL's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for DTIL.

See every catalyst's timing & PoA →